On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant. To listen to more podcasts from ASCO, visit <a href= "https://old-prod.asco.org/news-initiatives/podcasts">asco.org/podcasts</a>.

On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant. To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of&nbsp;sacituzumab govitecan-hziy, and the January 27 approval of&nbsp;elacestrant. To listen to more podcasts from ASCO, visit <a href="https://old-prod.asco.org/news-initiatives/podcasts" rel="noopener noreferrer">asco.org/podcasts</a>.

Share Recent FDA Approvals for Patients With Breast Cancer

Sign up to save your podcasts

Recent FDA Approvals for Patients With Breast Cancer

Recent FDA Approvals for Patients With Breast Cancer

More shows like The ASCO Post Podcast

Research To Practice | Oncology Videos

ASCO Daily News